Combined with previous in vitro results, we suggest that GALNT5 confers chemotherapy resistance to FOLFIRINOX in pancreatic cancer cells by binding to MYH9 and inhibiting NOTCH signaling in vivo. This evidence concerns the gene MYH9 and pancreatic neoplasm.